CN110234660B - 睫状神经营养因子受体配体结合剂及其使用方法 - Google Patents

睫状神经营养因子受体配体结合剂及其使用方法 Download PDF

Info

Publication number
CN110234660B
CN110234660B CN201780084930.1A CN201780084930A CN110234660B CN 110234660 B CN110234660 B CN 110234660B CN 201780084930 A CN201780084930 A CN 201780084930A CN 110234660 B CN110234660 B CN 110234660B
Authority
CN
China
Prior art keywords
cntfr
polypeptide
soluble
clcf1
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780084930.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN110234660A (zh
Inventor
金准宇
詹妮弗·R·科克伦
埃里克·亚历杭德罗·斯威特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to CN202410001971.1A priority Critical patent/CN118141922A/zh
Publication of CN110234660A publication Critical patent/CN110234660A/zh
Application granted granted Critical
Publication of CN110234660B publication Critical patent/CN110234660B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
CN201780084930.1A 2016-12-06 2017-12-06 睫状神经营养因子受体配体结合剂及其使用方法 Active CN110234660B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410001971.1A CN118141922A (zh) 2016-12-06 2017-12-06 睫状神经营养因子受体配体结合剂及其使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662430757P 2016-12-06 2016-12-06
US62/430,757 2016-12-06
US201762481027P 2017-04-03 2017-04-03
US62/481,027 2017-04-03
PCT/US2017/064883 WO2018106790A1 (en) 2016-12-06 2017-12-06 Ciliary neurotrophic factor receptor ligand-binding agents and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410001971.1A Division CN118141922A (zh) 2016-12-06 2017-12-06 睫状神经营养因子受体配体结合剂及其使用方法

Publications (2)

Publication Number Publication Date
CN110234660A CN110234660A (zh) 2019-09-13
CN110234660B true CN110234660B (zh) 2024-01-12

Family

ID=62491581

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780084930.1A Active CN110234660B (zh) 2016-12-06 2017-12-06 睫状神经营养因子受体配体结合剂及其使用方法
CN202410001971.1A Pending CN118141922A (zh) 2016-12-06 2017-12-06 睫状神经营养因子受体配体结合剂及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410001971.1A Pending CN118141922A (zh) 2016-12-06 2017-12-06 睫状神经营养因子受体配体结合剂及其使用方法

Country Status (8)

Country Link
US (2) US11208462B2 (https=)
EP (1) EP3551648A4 (https=)
JP (1) JP7257680B2 (https=)
KR (1) KR102667654B1 (https=)
CN (2) CN110234660B (https=)
AU (1) AU2017370653B2 (https=)
CA (1) CA3045925A1 (https=)
WO (1) WO2018106790A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4028044A4 (en) * 2019-09-10 2023-09-27 The Board of Trustees of the Leland Stanford Junior University Methods of treating kras mutant cancers
MA71452A (fr) * 2022-07-12 2025-04-30 Regeneron Pharmaceuticals, Inc. Anticorps dirigés contre le récepteur du facteur neurotrophique ciliaire (cntfr) et leurs procédés d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1494593A (zh) * 2001-03-02 2004-05-05 Ĭ��ר�����޹�˾ 具有降低免疫原性的经修饰睫状神经营养因子(cntf)
CN1760205A (zh) * 2005-09-02 2006-04-19 中国药品生物制品检定所 睫状神经营养因子(cntf)突变体及其生产方法和其用途
WO2012175378A1 (de) * 2011-06-18 2012-12-27 Christian-Albrechts-Universität Zu Kiel Ciliary-neurotrophic-factor-varianten

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426177A (en) * 1990-06-01 1995-06-20 Regeneron Pharmaceuticals, Inc. Ciliary neurotrophic factor receptor
CN1061623A (zh) * 1990-06-01 1992-06-03 里珍纳龙药品有限公司 睫状神经营养性因子受体
IT1284867B1 (it) * 1996-07-10 1998-05-22 Angeletti P Ist Richerche Bio Varianti del fattore neurotrofico ciliare umano (hcntf) con uno spettro di azione differente dalla molecola di tipo selvatico
US20080254451A1 (en) * 2004-12-28 2008-10-16 Ares Trading S.A. Compositions and Methods for Treating Schizophrenia and Related Disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1494593A (zh) * 2001-03-02 2004-05-05 Ĭ��ר�����޹�˾ 具有降低免疫原性的经修饰睫状神经营养因子(cntf)
CN1760205A (zh) * 2005-09-02 2006-04-19 中国药品生物制品检定所 睫状神经营养因子(cntf)突变体及其生产方法和其用途
WO2012175378A1 (de) * 2011-06-18 2012-12-27 Christian-Albrechts-Universität Zu Kiel Ciliary-neurotrophic-factor-varianten

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Alanine Substitution for Thr268 and Asp269 of Soluble Ciliary Neurotrophic Factor (CNTF) Receptor α Component Defines a Specific Antagonist for the CNTF Response;Patrick Auguste等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;pubmed;19961018;第271卷(第42期);摘要，第26050页右栏第4段 *
Ciliary Neurotrophic Factor，Cardiotrophin-like Cytokine，and Neuropoietin Share a Conserved Binding Site on the Ciliary Neurotrophic Factor Receptor α Chain;Francois Rousseau等;《THE JOURNAL OF BIOLOGICAL CHEMISTRY》;pubmed;20081031;第283卷(第44期);摘要 *
Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect ofcardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier;MUKUT SHARMA等;《Translational Research》;pubmed;20151031;第166卷(第4期);摘要 *
Patrick Auguste等.Alanine Substitution for Thr268 and Asp269 of Soluble Ciliary Neurotrophic Factor (CNTF) Receptor α Component Defines a Specific Antagonist for the CNTF Response.《THE JOURNAL OF BIOLOGICAL CHEMISTRY》.pubmed,1996,第271卷(第42期), *
睫状神经营养因子受体;何成等;《生物化学与生物物理进展》;维普;19961231(第3期);第205-208页 *

Also Published As

Publication number Publication date
JP7257680B2 (ja) 2023-04-14
US11208462B2 (en) 2021-12-28
EP3551648A4 (en) 2020-07-29
KR20190103172A (ko) 2019-09-04
US20220213171A1 (en) 2022-07-07
KR102667654B1 (ko) 2024-05-22
JP2019536802A (ja) 2019-12-19
WO2018106790A1 (en) 2018-06-14
EP3551648A1 (en) 2019-10-16
AU2017370653B2 (en) 2022-07-21
CN110234660A (zh) 2019-09-13
AU2017370653A1 (en) 2019-07-25
CN118141922A (zh) 2024-06-07
CA3045925A1 (en) 2018-06-14
US20190359683A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
CN106414498B (zh) TNF α的结合成员
US20220331401A1 (en) Methods of treating kras mutant cancers
US20220226435A1 (en) Ciliary Neurotrophic Factor Receptor Ligands and Methods of Using the Same
JP2019511201A (ja) 前立腺特異的膜抗原（ｐｓｍａ）と結合する分子
JP2020530285A (ja) 治療的ｐｓｍａ結合分子
JP2008515889A (ja) 毒性の低下した治療剤
CA2868575C (en) Sh2 domain variants
US20220211861A1 (en) Drug conjugates and methods of using same
US20220213171A1 (en) Ciliary Neurotrophic Factor Receptor Ligand-Binding Agents and Methods of Using the Same
CN115916234A (zh) 靶向ras蛋白的分子
EP3262069B1 (en) Use of antibodies and antagonists directed against lrg1 in treatment
JP2026509871A (ja) 抗ｌｉｖ－１抗体及び抗ｌｉｖ－１抗体薬物複合体並びにその薬物的使用
HK40014589A (en) Ciliary neurotrophic factor receptor ligand-binding agents and methods of using the same
US12049490B2 (en) Soluble leukemia inhibitory factor receptor polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity
KR20220143730A (ko) 단백질을 표적화하는 분자
HK40014589B (zh) 睫状神经营养因子受体配体结合剂及其使用方法
US20190099506A1 (en) Methods and compositions for deuterated biologics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40014589

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant